Trinity Biotech (TRIB) Stock Price
Trinity Biotech Price
Trinity Biotech (TRIB) Stock | ISIN US8964385046 | WKN A0ET3S. The current Trinity Biotech stock price is 0.58 USD (2026). Revenue is 79.05 M USD. Net income is -176.53 M USD. The P/E ratio is -0.23. Market capitalization is 204.86 M USD. Trinity Biotech operates in the Health sector.
Revenue at Trinity Biotech has contracted by 2.4% per year over the past 19 years to 61.56 M USD. Earnings per share have declined at 20.4% per year over the last 16 years. For Trinity Biotech, the net margin of -51.6% is down versus -6.3% a few years ago. At today's price the dividend yield works out to roughly 37.93%. The payout ratio is around 109% of earnings. The dividend has grown at 21.8% per year over the past 4 years.
Trinity Biotech stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Trinity Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Trinity Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Trinity Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Trinity Biotech Price |
|---|
Trinity Biotech Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Trinity Biotech Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025e | 2026e |
|---|---|---|---|---|---|---|---|
| 90 | 101 | 81 | 62 | 56 | 61 | 69 | 79 |
| -7.22 | 12.22 | -19.8 | -23.46 | -9.68 | 8.93 | 13.11 | 14.49 |
| 42.22 | 47.52 | 40.74 | 27.42 | 33.93 | 34.43 | 30.43 | 26.58 |
| 38 | 48 | 33 | 17 | 19 | 21 | 21 | 21 |
| -28 | -6 | 0 | -41 | -24 | -31 | -324 | -176 |
| 27.27 | -78.57 | – | – | -41.46 | 29.17 | 945.16 | -45.68 |
| 83.61 | 83.61 | 83.61 | 134.94 | 153.1 | 353.21 | 353.21 | 353.21 |
| – | – | – | – | – | – | – | – |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Trinity Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Trinity Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Trinity Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Trinity Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Trinity Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Trinity Biotech stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Trinity Biotech Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Trinity Biotech business model & stock analysis
Trinity Biotech Segments
Trinity Biotech Revenue by Segment
3 Years
Max
Details
Trinity Biotech Revenue by Region
3 Years
Max
Details
Trinity Biotech Eulerpool Fair Value
Trinity Biotech historical P/E ratio, EBIT multiple, and P/S ratio
Trinity Biotech annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Trinity Biotech shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Trinity Biotech Dividend History
5 years of dividend payments
Trinity Biotech dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Trinity Biotech Earnings Estimates
Trinity Biotech Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/3/2026 | -0.17USD | 18.36 MUSD | 2025 Q4 |
| 8/13/2025 | -0.24USD | 17.85 MUSD | 2025 Q2 |
| 12/14/2022 | -0.04USD | 19.79 MUSD | 2022 Q3 |
| 11/3/2022 | -0.3USD | 18.74 MUSD | 2022 Q2 |
| 6/30/2022 | -0.04USD | 20.3 MUSD | 2022 Q1 |
| 4/11/2022 | 0.07USD | 24.36 MUSD | 2021 Q4 |
| 5/25/2021 | 0.07USD | -USD | 2021 Q1 |
| 3/25/2021 | 0.14USD | 28.42 MUSD | 2020 Q4 |
| 11/17/2020 | 0.1USD | 28.42 MUSD | 2020 Q3 |
| 3/31/2020 | 0.06USD | -USD | 2019 Q4 |
EESG©
Eulerpool ESG Scorecard© for the Trinity Biotech stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Trinity Biotech shareholder structure
| % | Name |
|---|---|
0.50678% | |
0.13791% | |
0.12672% | |
0.00727% | |
0.00464% | |
0.00357% | |
0.0034% | |
0.00323% | |
0.00283% | |
0.00191% |
Trinity Biotech Executives and Management Board
Mr. John Gillard
(43)President, Chief Executive Officer, Executive Director · since 2020
Mr. Ronan O'caoimh
(68)Founder, Executive Director · since 1992
Dr. James Walsh
(65)Executive Director - Business Development · since 2005
Mr. Tom Lindsay
(67)Non-Executive Independent Director
Mr. Andrew Omidvar
Non-Executive Independent Director
Trinity Biotech Supply Chain
Frequently asked questions about Trinity Biotech
Trinity Biotech stock
Trinity Biotech Peer Group
Trinity Biotech Ticker
All fundamentals and in-depth analysis of Trinity Biotech
Our stock analysis for Trinity Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Trinity Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.